Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade A 110.475 0.43% 0.48
CELG closed up 0.39 percent on Tuesday, November 12, 2019, on 1.16 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical CELG trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 37.36%
Gilligan's Island Sell Setup Bearish Swing Setup 37.36%
Crossed Above 20 DMA Bullish 37.36%
Crossed Above 50 DMA Bullish 37.36%
New Uptrend Bullish 37.36%
Expansion Breakout Bullish Swing Setup 37.36%
Pocket Pivot Bullish Swing Setup 37.36%
Volume Surge Other 37.36%
Above Upper BB Strength 37.36%
Gapped Up Strength 37.36%

Older signals for CELG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Medicine Chemistry Cancer New Jersey Chemotherapy Acute Myeloid Leukemia Multiple Myeloma Antineoplastic Drugs Anemia Immunosuppressants Celgene Solid Tumor Therapies For Cancer Metastatic Breast Cancer Summit Aromatic Amines Myelodysplastic Syndromes Myelofibrosis PDA Ace 536 Cutaneous T Cell Lymphoma Immune Inflammatory Related Diseases Lenalidomide Pomalidomide
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 110.47
52 Week Low 58.59
Average Volume 3,585,747
200-Day Moving Average 94.9707
50-Day Moving Average 101.8062
20-Day Moving Average 106.3055
10-Day Moving Average 108.557
Average True Range 1.1193
ADX 51.94
+DI 45.5915
-DI 9.0781
Chandelier Exit (Long, 3 ATRs ) 107.1121
Chandelier Exit (Short, 3 ATRs ) 103.469
Upper Bollinger Band 111.5232
Lower Bollinger Band 101.0878
Percent B (%b) 0.85
BandWidth 9.816425
MACD Line 2.4268
MACD Signal Line 2.2866
MACD Histogram 0.1402
Fundamentals Value
Market Cap 86.05 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 34.06
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 111.61
Resistance 3 (R3) 111.58 111.03 111.34
Resistance 2 (R2) 111.03 110.62 111.04 111.25
Resistance 1 (R1) 110.51 110.37 110.77 110.54 111.16
Pivot Point 109.96 109.96 110.09 109.97 109.96
Support 1 (S1) 109.44 109.55 109.70 109.47 108.84
Support 2 (S2) 108.89 109.30 108.90 108.75
Support 3 (S3) 108.37 108.89 108.66
Support 4 (S4) 108.40